Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population

References

• Zeng C, Chen H, Wang R, et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis. 2008;52(4):691–698. doi:10.1053/j.ajkd.2008.06.00618805348
   PubMed Web of Science ®Google Scholar
• Alfaadhel T, Cattran D. Management of membranous nephropathy in Western countries. Kidney Dis (Basel). 2015;1(2):126–137. doi:10.1159/00043728727536673
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704. doi:10.1681/ASN.200908086120110379
   PubMed Web of Science ®Google Scholar
• Quaglia M, Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs. 2009;69(10):1303–1317. doi:10.2165/00003495-200969100-0000219583450
   PubMed Web of Science ®Google Scholar
• Daniel C. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005;16(5):1188–1194. doi:10.1681/ASN.200501002815800117
   PubMed Web of Science ®Google Scholar
• Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis. 2004;44(3):562–566.15332231
   PubMed Web of Science ®Google Scholar
• Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899–1904. doi:10.1681/ASN.200702016617494881
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. Idiopathic membranous nephropathy: back to the future? Lancet. 2013;381(9868):706–708. doi:10.1016/S0140-6736(12)62033-923312809
   PubMed Web of Science ®Google Scholar
• Waldman M, Austin HR. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1617–1630. doi:10.1681/ASN.201201005822859855
   PubMed Web of Science ®Google Scholar
• Zhu L, Liu L, Yao L, et al. Efficacy and safety of tacrolimus versus cyclophosphamide for primary membranous nephropathy: a meta-analysis. Drugs. 2017;77(2):187–199. doi:10.1007/s40265-016-0683-z28084563
   PubMed Web of Science ®Google Scholar
• van Den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28(9):2729. doi:10.1681/ASN.201608088628487395
   PubMed Web of Science ®Google Scholar
• Goumenos DS. What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy? Expert Opin Pharmacother. 2008;9(10):1695–1704. doi:10.1517/14656566.9.10.169518570603
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Halevy D. Cyclosporin treatment of glomerular diseases. Expert Opin Investig Drugs. 2000;9(5):1053–1063. doi:10.1517/13543784.9.5.1053
   PubMed Web of Science ®Google Scholar
• Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. Semin Nephrol. 2003;23(4):362–372.12923724
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Cyclosporine: from renal transplantation to autoimmune diseases. Ann N Y Acad Sci. 2005;1051:551–558.16126995
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.19218475
   PubMed Web of Science ®Google Scholar
• Chen ZF, Zhang JW, Xia NN, et al. Comparison on the therapeutic effect of cyclosporine A and cyclophosphamide in the treatment of idiopathic membranous nephropathy. China Med Pharm. 2014;4(16):16–18.
   Google Scholar
• Deng SS, Zhu MZ, Bo M. Clinical observation of cyclosporine A versus cyclophosphamide in the treatment of idiopathic membranous nephropathy. Chin J Mod Drug Appl. 2018;12(14):125–127.
   Google Scholar
• Ding BB. Comparison of the effects of two therapeutic regimen in the treatment of idiopathic membranous nephropathy. Chin J Prim Med Pharm. 2014;21(21):3238–3241.
   Google Scholar
• Dong XH, Miu JL, Chen HL. The comparison of the clinical effect of cyclosporine A versus cyclophosphamide in the treatment of idiopathic membranous nephropathy. PJCCPVD. 2017;25(S1):80–81.
   Google Scholar
• Huang LL. The observation of long-term efficacy and safety of cyclosporine A combined with glucocorticoid in the treatment of idiopathic membranous nephropathy. Hebei Med. 2017;23(07):1202–1206.
   Google Scholar
• Huang ZM, Chen KJ. The observation of the efficacy, relapse rate and the side effect of cyclosporine A versus cyclophosphamide in the treatment of idiopathic membranous nephropathy. J North Pharm. 2016;13(9):66.
   Google Scholar
• Xie J, Guo W, Zhang QD, et al. Clinical effect of cyclophosphamide or tacrolimus combined with glucocorticoids in the treatment of idiopathic membranous nephropathy. Chin J Integr Tradit West Nephrol. 2014;15(08):716–718.
   Google Scholar
• Li LL. Clinical comparison of the hormone combined with different immunosuppressive agents in the treatment of idiopathic membranous nephropathy. Guide China Med. 2016;14(16):180–181.
   Google Scholar
• Liu AQ, Liu GP, Yu L, et al. Clinical observation of cyclosporine A in the treatment of idiopathic membranous nephropathy. Inner Mongolia Med J. 2016;48(12):1505–1506.
   Google Scholar
• Liu JC, An ZM, Zhang LC, et al. Efficacy of cyclosporine A combined with glucocorticoid in treatment of membranous nephropathy. J Qiqihar Univ Med. 2013;34(13):1910–1912.
   Google Scholar
• Liu LH, Ma SY, Liu ZY, et al. The observation of efficacy of cyclosporine A in the treatment of idiopathic membranous nephropathy. Anhui Med J. 2013;34(8):1217–1219.
   Google Scholar
• Liu HT. The observation of efficacy of cyclosporine A combined with glucocorticoid in the treatment of idiopathic membranous nephropathy. Chin J Prim Med Pharm. 2015;22(16):2467–2470.
   Google Scholar
• Sa RL. The analysis of safety and efficacy of cyclosporine A in the treatment of idiopathic membranous nephropathy. China Health Care Nutr. 2018;28(1):325–326.
   Google Scholar
• Wu QX, Gong ZF. Clinical observation of 20 cases of membranous nephropathy treated with low and medium dose cyclosporine. China Pharm. 2011;14(1):115–117.
   Google Scholar
• Yang J, Liu Y, Zhang Y, et al. Glucocorticoid and immunosuppressive therapy with high risk factors for idiopathic membranous nephropathy in 46 cases. Prog Mod Biomed. 2013;13(14):2710–2712.
   Google Scholar
• Zhang D. The observation of clinical efficacy of cyclosporine A versus cyclophosphamide in treatment of membranous nephropathy. Health Med Res Prac. 2016;13(04):50–51.
   Google Scholar
• Zhang M. Clinical observation of cyclophosphamide combined with glucocorticoid on membranous nephropathy. Chin J Biochem Pharm. 2016;36(1):121–123.
   Google Scholar
• Zhang X. Low-dose of cyclosporine and low-dose glucocorticoid in the treatment of idiopathic membranous nephropathy. Guide China Med. 2013;11(30):121–122.
   Google Scholar
• Choi J, Kim DK, Kim Y, et al. The effect of mycophenolate mofetil versus cyclosporine as combination therapy with low dose corticosteroids in high-risk patients with idiopathic membranous nephropathy: a multicenter randomized trial. J Korean Med Sci. 2018;33(9):e74.29441742
   PubMed Web of Science ®Google Scholar
• Guo Y. The observation of efficacy of the tacrolimus in the treatment of idiopathic membranous nephropathy. J North Pharm. 2016;13(9):61.
   Google Scholar
• Hu QF The Clinical Observation of the cyclosporine A Versus Tacrolimus Combined with Half-Dose of Glucocorticoid in the Treatment of Idiopathic Membranous Nephropathy [ doctoral dissertation]. Xinxiang: Xinxiang Medical University; 2016.
   Google Scholar
• Li QH The Clinical Observation of the cyclosporine A Versus Tacrolimus Combined with Half-Dose of Glucocorticoid in the Treatment of Idiopathic Membranous Nephropathy [ doctoral dissertation]. Zhengzhou: Zhengzhou University; 2017.
   Google Scholar
• Qiu TT, Zhang C, Zhao HW, et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev. 2017;16(2):136–145.27988429
   PubMed Web of Science ®Google Scholar
• Ren S, Wang Y, Xian L, et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis. PLoS One. 2017;12(9):e184398.
   PubMed Web of Science ®Google Scholar
• Xie G, Xu J, Ye C, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults. PLoS One. 2012;7(9):e44330.22957065
   PubMed Web of Science ®Google Scholar